Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer. Patients with previously treated, inoperable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback